News

Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...
Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock
Let's look at why this news could be a game-changer for Eli Lilly and its stock.
Is Eli Lilly Stock a Buy?
Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock ...
Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence
Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic ...
Eli Lilly initiated with an Overweight at Cantor Fitzgerald
As previously reported, Cantor Fitzgerald initiated coverage of Eli Lilly (LLY) with an Overweight rating and $975 price target Lilly is off ...